department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Vanrafia · pharmadog

pharmadog
drugs
Vanrafia

drug

patient view →

atrasentan hydrochloride

Marketedupdated 2mo ago

by $NVS NOVARTIS AG

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.

all catalysts(2)

approval · 2

VANRAFIA (ATRASENTAN HYDROCHLORIDE) — FDA approval

atrasentan hydrochloride

VANRAFIA (ATRASENTAN HYDROCHLORIDE) — FDA approval

atrasentan hydrochloride

News(0)

no news has mentioned this drug yet

brand

Vanrafia

generic

atrasentan hydrochloride

MOA

12.1 Mechanism of Action Atrasentan is an ET A receptor antagonist (Ki = 0.034 nM) with >1800-fold selectivity for the ET A receptor compared to the endothelin type B receptor (Ki = 63.3 nM). Endothelin (ET)-1 is thought to contribute to the pathogenesis of IgAN via the ET A R.

indication

IgA Nephropathy (Berger's Disease)

phase

marketed

$NVS159.90+3.74%

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 22, 2028

~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

Mar 25, 2043method-of-use (U-3980)US 12582631
Feb 23, 2041method-of-use (U-3980)US 12521369
Dec 16, 2040method-of-use (U-3980)US 11491137
Dec 16, 2040method-of-use (U-3980)US 11998526
Dec 16, 2040method-of-use (U-3980)US 12121509
Dec 16, 2040method-of-use (U-3980)US 12370174
Jul 7, 2034formulationUS 10016393
Jul 7, 2034formulationUS 9364458
Feb 18, 2032method-of-use (U-3980)US 11874283
Aug 22, 2028method-of-use (U-3980)US 86238192.1y

FDA exclusivities (1)

Apr 2, 2030NCENew Chemical Entity (5y)3.7y

$NVS159.90+3.74%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

drugVANRAFIA8 co-mentions · 2 sources
tagApproval8 co-mentions · 2 sources
tagSmall Molecule4 co-mentions · 2 sources